Assess whether scientific advice should be sought before the next trial

SITUATION A mid-size sponsor after a complete response letter has 505(b)(2) literature-to-product bridge table in hand following an AdCom briefing document that overstates subgroup findings. 505(b)(2) development lead must determine whether scientific advice should be sought before the next trial for this Pharma & Life Sciences Clinical and Evidence Strategy file.

DECISION 505(b)(2) development lead in a mid-size sponsor after a complete response letter must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using 505(b)(2) literature-to-product bridge table after an AdCom briefing document that overstates subgroup findings.

HYPOTHESES TO TEST 1. 505(b)(2) literature-to-product bridge table reads as Proceed under protocol once an AdCom briefing document that overstates subgroup findings is lined up to the same Pharma & Life Sciences population. 2. 505(b)(2) literature-to-product bridge table is closer to Pause the pathway after an AdCom briefing document that overstates subgroup findings; Proceed under protocol would over-claim this Clinical and Evidence Strategy extract. 3. Escalate safety review is still live in 505(b)(2) literature-to-product bridge table for 505(b)(2) development lead in a mid-size sponsor after a complete response letter. 4. 505(b)(2) literature-to-product bridge table is missing the fact 505(b)(2) development lead needs after an AdCom briefing document that overstates subgroup findings; stop this Pharma & Life Sciences close.

ANALYSIS REQUIRED 1. Check whether 505(b)(2) literature-to-product bridge table supports the labeled claim 505(b)(2) development lead would keep. 2. Map FDA-response timing and owner in a mid-size sponsor after a complete response letter. 3. Trace CMC, labeling, or pharmacovigilance facts in 505(b)(2) literature-to-product bridge table after an AdCom briefing document that overstates subgroup findings. 4. For this Pharma & Life Sciences Clinical and Evidence Strategy file, read 505(b)(2) literature-to-product bridge table against an AdCom briefing document that overstates subgroup findings and write the one fact that would move scientific advice should be for 505(b)(2) development lead.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / Clinical and Evidence Strategy packet (505(b)(2) literature-to-product bridge table after an AdCom briefing document that overstates subgroup findings). The follow-on Clinical and Evidence Strategy action is what 505(b)(2) development lead does next: implement the option, assign an owner, and log the missing fact.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on scientific advice should be, then the evidence in 505(b)(2) literature-to-product bridge table, then the action for 505(b)(2) development lead - Hypothesis scorecard against 505(b)(2) literature-to-product bridge table: supported / rejected / untestable - What changes scientific advice should be if an AdCom briefing document that overstates subgroup findings is later withdrawn - Named option among Proceed under protocol, Pause the pathway, Escalate safety review and the fact that kills the others